This report presents the recommendations of a WHO Expert Committee responsible for updating and revising the Model List of Essential Drugs. The first part provides guidance for countries wishing to establish national programmes for essential drugs, and includes discussion of quality assurance, post-registration drug studies, drug information and educational activities, research and development, and antiviral drugs. In the light of increasing antimicrobial resistance, particular attention is drawn to the use of reserve antimicrobials. The second part presents the ninth revised model list, together with details of changes that have been made, a glossary of terms and an alphabetical list of all the drugs included.